Cancer Supportive Care Drug Development Pipeline Review 2017 - Research and Markets

DUBLIN--()--The "Cancer Supportive Care Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.

There are a total of 24 products in development for this indication, by 18 companies and four academic institutions.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. There are a total of 32 products in development for this indication, by 22 companies and four academic institutions. Key companies operating in this pipeline space include MetCure Therapeutics, Applied Integrin Sciences, Eli Lilly, and Tel Aviv University.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. There are a total of 52 products in development for this indication, by 40 companies and four academic institutions. Key companies operating in this pipeline space include Komipharm, Trillium Therapeutics, AstraZeneca, Insys Therapeutics, Klaria Pharma and Pharmaleads.

The majority of products in cancer anorexia-cachexia syndrome target the growth hormone secretagogue receptor type 1, although there are a range of other molecular targets in development. Within bone metastasis, the most common molecular targets are the tumor necrosis factor ligand superfamily member 11, and the hepatocyte growth factor receptor, along with a range of others. Finally, within cancer pain, neurotransmitters such as the mu type opioid receptor, and a range of ion channels, are the most common type of target, reflecting the pain treatment landscape in general.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1 List of Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/4k86p3/cancer_supportive?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Oncology Drugs